CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
S2312 SWOG A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature Adult CIRB - Late Phase Emphasis
S2408 SWOG A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula Cancer Prevention and Control CIRB
S2409 SWOG PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) Adult CIRB - Late Phase Emphasis
S2414 SWOG Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non-Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) Adult CIRB - Late Phase Emphasis
S2417CD SWOG A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance Cancer Prevention and Control CIRB
S2419 SWOG Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial] Adult CIRB - Late Phase Emphasis
S2427 SWOG Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) Adult CIRB - Late Phase Emphasis
S2433 SWOG Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma Adult CIRB - Late Phase Emphasis
S2505 SWOG Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) versus Standard Fractionation (RT-25) for Stage II-IIIB Extremity, Resectable Soft Tissue Sarcoma Adult CIRB - Late Phase Emphasis
S2506 SWOG MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination with Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Participants with Relapsed/Refractory Marginal Zone Lymphoma Adult CIRB - Late Phase Emphasis